Millennium Management LLC Has $847,000 Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Millennium Management LLC lifted its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 417.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 76,829 shares of the company's stock after buying an additional 61,994 shares during the period. Millennium Management LLC owned about 0.15% of Stoke Therapeutics worth $847,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of STOK. Rhumbline Advisers grew its position in Stoke Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after acquiring an additional 2,787 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Stoke Therapeutics by 8.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company's stock valued at $3,774,000 after purchasing an additional 25,995 shares during the last quarter. Swiss National Bank increased its position in Stoke Therapeutics by 20.4% during the 4th quarter. Swiss National Bank now owns 67,300 shares of the company's stock worth $742,000 after purchasing an additional 11,400 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new position in Stoke Therapeutics in the 4th quarter valued at approximately $113,000.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Chardan Capital reaffirmed a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reduced their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Stoke Therapeutics has an average rating of "Buy" and an average price target of $23.20.

Stoke Therapeutics Price Performance

NASDAQ STOK traded up $0.23 on Tuesday, reaching $11.36. The company had a trading volume of 445,082 shares, compared to its average volume of 701,490. The firm has a market cap of $620.22 million, a price-to-earnings ratio of -5.41 and a beta of 1.09. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The business has a 50 day moving average of $8.96 and a two-hundred day moving average of $9.65.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. As a group, research analysts predict that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 6,471 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the completion of the sale, the insider now directly owns 25,782 shares in the company, valued at $258,593.46. This represents a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,748 shares of company stock worth $225,687. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.